Efficacy in gastrointestinal stromal tumours must be confirmed

Prescrire International

Volumn 12, Issue 67, 2003, Pages 163-164

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; CYTOTOXIC AGENT; IMATINIB; PARACETAMOL; WARFARIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; EDEMA; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIVER DYSFUNCTION; MALIGNANT TRANSFORMATION; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; RASH; SKIN MANIFESTATION; SURVIVAL TIME; TREATMENT FAILURE; TUMOR REGRESSION; VOMITING; WATER RETENTION; COMPARATIVE STUDY; DRUG ANTAGONISM; FRANCE; GASTROINTESTINAL TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG APPROVAL; FRANCE; GASTROINTESTINAL NEOPLASMS; HUMANS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 0642309448     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Prescrire Editorial Staff "Imatinib" Prescr Int 2003; 12 (64): 49-52.
2. Joensuu H et al. "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastro-intestinal stromal tumor" N Engl J Med 2001; 344 (14): 1052-1056.
3. van Oosterom AT et al. "Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumors: a phase I study" Lancet 2001; 358: 1421-1423.
4. Demetri GD et al. "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" N Engl J Med 2002; 347 (7): 472-480.
5. Agence française de sécurité sanitaire des produits de santé - Commission de la transparence" Avis de la commission- Glivec°" 4 December 2002: 6 pages.
6. Demetri GD et al. "Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 early results" ASCO 2002; abstr. 1651 (1 page).
7. Casali PG et al. "Imatinib (Glivec) 400 versus 800 mg daily in patients with gastrointestinal stromal tumors (GIST): a randomized phase III trial from the EORTC soft tissue and bone sarcoma group, the Italian sarcoma group (ISG), and the Australasian gastro-intestinal trials group (AGITG). A toxicity report" ASCO 2002: abstr. 1650 (1 page).
8. Novartis Pharma "Imatinib. Treatment of unresectable and/or metastatic malignant gastro-intestinal stromal tumors (GIST). Expert report on the clinical documentation" 24 October 2001: 27 pages.